215 related articles for article (PubMed ID: 20717900)
1. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.
Wieckowski E; Chatta GS; Mailliard RM; Gooding W; Palucka K; Banchereau J; Kalinski P
Prostate; 2011 Feb; 71(2):125-33. PubMed ID: 20717900
[TBL] [Abstract][Full Text] [Related]
2. Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells.
Hwang EC; Lim MS; Im CM; Kwon DD; Lee HJ; Nguyen-Pham TN; Lee YK; Lee JJ
Scand J Immunol; 2013 Feb; 77(2):117-24. PubMed ID: 23126536
[TBL] [Abstract][Full Text] [Related]
3. Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy.
Hansen M; Hjortø GM; Donia M; Met Ö; Larsen NB; Andersen MH; thor Straten P; Svane IM
Vaccine; 2013 Jan; 31(4):639-46. PubMed ID: 23200882
[TBL] [Abstract][Full Text] [Related]
4. Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins.
Yang DH; Kim MH; Lee YK; Hong CY; Lee HJ; Nguyen-Pham TN; Bae SY; Ahn JS; Kim YK; Chung IJ; Kim HJ; Kalinski P; Lee JJ
Ann Hematol; 2011 Dec; 90(12):1419-26. PubMed ID: 21465188
[TBL] [Abstract][Full Text] [Related]
5. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.
Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC
Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216
[TBL] [Abstract][Full Text] [Related]
6. Generation of potent cytotoxic T lymphocytes against in male patients with non-muscle invasive bladder cancer by dendritic cells loaded with dying T24 bladder cancer cells.
Hwang EC; Jung SI; Lee HJ; Lee JJ; Kwon DD
Int Braz J Urol; 2017; 43(4):615-627. PubMed ID: 28266813
[TBL] [Abstract][Full Text] [Related]
7. Tumour-loaded α-type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia produce a superior NK-, NKT- and CD8+ T cell-attracting chemokine profile.
Gustafsson K; Junevik K; Werlenius O; Holmgren S; Karlsson-Parra A; Andersson PO
Scand J Immunol; 2011 Sep; 74(3):318-326. PubMed ID: 21595737
[TBL] [Abstract][Full Text] [Related]
8. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia.
Lee JJ; Foon KA; Mailliard RB; Muthuswamy R; Kalinski P
J Leukoc Biol; 2008 Jul; 84(1):319-25. PubMed ID: 18426971
[TBL] [Abstract][Full Text] [Related]
9. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
10. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
11. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
Olson BM; Frye TP; Johnson LE; Fong L; Knutson KL; Disis ML; McNeel DG
Cancer Immunol Immunother; 2010 Jun; 59(6):943-53. PubMed ID: 20140431
[TBL] [Abstract][Full Text] [Related]
12. Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.
Trepiakas R; Pedersen AE; Met O; Hansen MH; Berntsen A; Svane IM
Vaccine; 2008 Jun; 26(23):2824-32. PubMed ID: 18450338
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses.
Nouri-Shirazi M; Banchereau J; Bell D; Burkeholder S; Kraus ET; Davoust J; Palucka KA
J Immunol; 2000 Oct; 165(7):3797-803. PubMed ID: 11034385
[TBL] [Abstract][Full Text] [Related]
16. The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization.
Ten Brinke A; Karsten ML; Dieker MC; Zwaginga JJ; van Ham SM
Vaccine; 2007 Oct; 25(41):7145-52. PubMed ID: 17719152
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
18. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.
Forsberg O; Carlsson B; Malmström PU; Ullenhag G; Tötterman TH; Essand M
Prostate; 2009 Jan; 69(1):70-81. PubMed ID: 18814178
[TBL] [Abstract][Full Text] [Related]
19. A bacterial flagellin in combination with proinflammatory cytokines activates human monocyte-derived dendritic cells to generate cytotoxic T lymphocytes having increased homing signals to cancer.
Hong CY; Kim SY; Lee HJ; Lee SE; Lim SC; Rhee JH; Lee JJ
J Immunother; 2014 Jan; 37(1):16-25. PubMed ID: 24316552
[TBL] [Abstract][Full Text] [Related]
20. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12.
Zou W; Borvak J; Marches F; Wei S; Galanaud P; Emilie D; Curiel TJ
J Immunol; 2000 Oct; 165(8):4388-96. PubMed ID: 11035076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
